Repligen Corporation logo

Repligen Corporation (1RGEN)

Market Closed
14 Jul, 15:30
XMIL XMIL
121. 60
0
0%
- Market Cap
212.35 P/E Ratio
- Div Yield
87 Volume
1.46 Eps
121.6
Previous Close
Add Transaction
Day Range
121.6 121.6
Year Range
96.34 140.1
Want to track 1RGEN and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

1RGEN closed Tuesday higher at €121.6, an increase of 0% from Monday's close, completing a monthly increase of 26.2196% or €25.26. Over the past 12 months, 1RGEN stock lost -7.1047%.
1RGEN is not paying dividends to its shareholders.
The last earnings report, released on May 05, 2026, missed the consensus estimates by -0.4474%. On average, the company has fell short of earnings expectations by -0.2804%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 6 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).

1RGEN Chart

Repligen (RGEN) Down 3.2% Since Last Earnings Report: Can It Rebound?

Repligen (RGEN) Down 3.2% Since Last Earnings Report: Can It Rebound?

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?

Zacks | 1 month ago
Repligen Has A Cleaner Recovery Angle, But With High Valuation

Repligen Has A Cleaner Recovery Angle, But With High Valuation

Repligen Has A Cleaner Recovery Angle, But With High Valuation

Seekingalpha | 1 month ago
Repligen Corporation (RGEN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Repligen Corporation (RGEN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Repligen Corporation (RGEN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seekingalpha | 2 months ago

Repligen Corporation (1RGEN) FAQ

What is the stock price today?

The current price is €121.60.

On which exchange is it traded?

Repligen Corporation is listed on XMIL.

What is its stock symbol?

The ticker symbol is 1RGEN.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has Repligen Corporation ever had a stock split?

No, there has never been a stock split.

Repligen Corporation Profile

Electronic Equipment, Instruments & Components Industry
Information Technology Sector
Olivier Loeillot CEO
XMIL Exchange
US7599161095 ISIN
US Country
2,000 Employees
- Last Dividend
- Last Split
26 Mar 1990 IPO Date

Overview

Repligen Corporation is an innovative force in the biotechnological industry, primarily focusing on the development and commercialization of bioprocessing technologies and systems that play a crucial role in biological drug manufacturing. With a global reach that extends across North America, Europe, the Asia Pacific, and additional international markets, Repligen stands at the forefront of facilitating the production of biological drugs. The company, incorporated in 1981 and based in Waltham, Massachusetts, has established itself as a pivotal contributor to the biopharmaceutical and diagnostics sectors by offering a robust portfolio of products designed to enhance the efficiency and productivity of drug manufacturing processes. Through strategic collaboration agreements, such as with Navigo Proteins GmbH, Repligen continues to expand its technological arsenal, ensuring it remains synonymous with innovation and quality in the bioprocessing industry.

Products and Services

  • Protein A Ligands and Cell Culture Growth Factor Products: They serve as the binding components of Protein A affinity chromatography resins, crucial for purifying biologics, alongside products designed to enhance cell culture growth, thereby increasing the yield of bioprocesses.
  • Chromatography Products: This encompasses OPUS pre-packed chromatography columns for biologics purification, alongside smaller-scale columns used in process development, viral clearance, and process validation studies, reinforcing the versatility and efficiency of bioprocessing workflows.
  • ELISA Test Kits and CaptivA Resins: These are essential for the detection and quantification of various biological agents, with chromatography resins under the CaptivA brand further supporting the purification stages of drug manufacturing.
  • Filtration Products: The line includes XCell Alternating Tangential Flow systems for upstream perfusion and cell culture, TangenX cassettes, and KrosFlo systems for downstream processing like drug concentration and buffer exchange, alongside Spectra/Por dialysis products and ProConnex flow paths, showcasing a comprehensive range of solutions for biologic drug filtration needs.
  • Process Analytics Products: With slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands, Repligen offers innovative solutions for process analytics, enabling more efficient and accurate monitoring and optimization of bioprocessing parameters.

Contact Information

Address: Building 1
Phone: 781 250 0111